Praluent sponsors Sanofi and Regeneron Pharmaceuticals Inc. held negotiations with FDA over labeling language and post-marketing requirements that would set the benchmark for Amgen Inc.'s talks with the agency on Repatha a month later.
By virtue of being a few weeks ahead in the PCSK9 inhibitor approval queue – thanks to a priority review voucher – Sanofi and Regeneron had a hand in shaping what the labeled target population and post-approval safety studies